Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 6/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16401520 | 1.00 | MMP9 (0.47) | MMP9TDP1POLBGAACA2 | |
| SCHEMBL2213327 | 0.88 | MMP9 (0.60) | MMP9TDP1POLBGAACA2 | |
| SCHEMBL669507 | 0.88 | MMP9 (0.60) | MMP9TDP1POLBGAACA2 | |
| SCHEMBL11146335 | 0.81 | GAA (0.51) | MMP9TDP1POLBGAACA2 | |
| SCHEMBL1023659 | 0.79 | GAA (0.47) | MMP9GAAALDH1A1MAPTTHRB | |
| SCHEMBL1469951 | 0.77 | POLB (0.52) | MMP9POLBGAAMMP2ADAMTS4 | |
| SCHEMBL27488248 | 0.77 | POLB (0.52) | MMP9POLBGAAMMP2ADAMTS4 | |
| Tpck SCHEMBL927265 | 0.77 | MMP9 (0.61) | MMP9TDP1POLBGAACA2 | |
| Tpck SCHEMBL441444 | 0.77 | MMP9 (0.61) | MMP9TDP1POLBGAACA2 | |
| SCHEMBL433895 | 0.75 | MMP9 (0.69) | MMP9TDP1POLBCA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692344-A1 | SELF-AMPLIFYING RNA CONSTRUCT AND USE THEREOF | Microuni Co., Ltd. (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034205-A1 | MODIFIED LIVE ATTENUATED FLU VIRUS VACCINES AND USES THEREOF | US AGRICULTURE (US) | 2026-02-05 | — | — | US | disclosed |
| US-12421301-B2 | Anti-influenza neuraminidase monoclonal antibodies and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250290095-A1 | Trans-Replicating RNA | BioNTech SE (DE) | 2025-09-18 | — | — | US | disclosed |
| US-20250250548-A1 | METHODS AND COMPOSITIONS FOR TREATING NEGATIVE-SENSE SINGLE-STRANDED RNA VIRUS | THE UNIVERSITY OF CHICAGO (US) | 2025-08-07 | — | — | US | disclosed |
| US-12370236-B2 | Method and combination for the suppression of COVID-19 virus | NATIONAL TSING HUA UNIVERSITY (TW) | 2025-07-29 | — | — | US | disclosed |
| US-12338448-B2 | Trans-replicating RNA | TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2025-06-24 | — | — | US | disclosed |
| US-12227769-B2 | Methods and compositions for treating negative-sense single-stranded RNA virus | THE UNIVERSITY OF CHICAGO (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2024181753-A1 | SELF-AMPLIFYING RNA CONSTRUCT AND USE THEREOF | 주식회사 마이크로유니 | 2024-09-06 | — | — | WO | disclosed |
| US-20240254205-A1 | ANTI-INFLUENZA NEURAMINIDASE MONOCLONAL ANTIBODIES AND USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2024-08-01 | — | — | US | disclosed |
| WO-2015196150-A2 | MUTATIONS THAT CONFER GENETIC STABILITY TO ADDITIONAL GENES IN INFLUENZA VIRUSES | WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150232454-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150224187-A1 | ATTENUATED INFLUENZA VACCINES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-08-13 | — | — | US | disclosed |
| WO-2015010073-A1 | ATTENUATED INFLUENZA VACCINES AND USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014043252-A2 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-03-20 | — | — | WO | disclosed |
| US-7592169-B2 | Methods and compositions for treatment and prevention of HSV-2 infections and conditions | MEDIMMUNE, LLC (US) | 2009-09-22 | — | — | US | disclosed |
| US-20050112142-A1 | Methods and compositions for treatment and prevention of HSV-2 infections and conditions | MEDIMMUNE, LLC | 2005-05-26 | — | — | US | disclosed |
| US-5922328-A | HERPES SIMPLEX | AVIRON (US) | 1999-07-13 | — | — | US | disclosed |
| WO-1997009999-A9 | METHODS AND COMPOSITIONS FOR TREATMENT OF HSV-2 INFECTIONS AND CONDITIONS | — | 1997-11-06 | — | — | WO | disclosed |
| WO-1997009999-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HSV-2 INFECTIONS AND CONDITIONS | AVIRON (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232454-A1 | THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES | XDH, DPYD, DHX15 | MMP9 2501/4885TDP1 101/4885POLB 1717/4885 |
| US-20260034205-A1 | MODIFIED LIVE ATTENUATED FLU VIRUS VACCINES AND USES THEREOF | IL2RA, IL36G, TRRAP | MMP9 4242/4885TDP1 3699/4885POLB 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.